Viral RNA clears from the bloodstream, antibodies stabilize, yet symptoms continue. This persistence despite apparent viral clearance has challenged clinicians for decades. Recent research into viral reservoirs, immune dysregulation, and mitochondrial dysfunction is starting to provide answers.

Historical Recognition of Post-Viral Illness

The idea of post-viral symptoms is not recent. Nineteenth-century medical literature documented individuals who struggled to fully recover after influenza outbreaks, describing “lingering exhaustion” and cognitive complaints similar to today’s post-viral syndromes. The 1918 influenza pandemic demonstrated the same pattern, with survivors reporting prolonged tiredness, muscle pain, and neurological symptoms after recovery. These early observations established the basis for modern recognition of post-infection illness.

By the late twentieth century, certain post-viral conditions gained more formal medical recognition. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) was increasingly linked to viral precursors such as Epstein-Barr Virus (EBV). Similarly, post-polio syndrome (weakness and fatigue appearing decades after initial infection) demonstrated the long-term effects of viral disease. These states highlighted the difficult and often unpredictable long-term effects of viral disease.

The COVID-19 pandemic has increased public health awareness of post-viral syndromes. Persistent symptoms after SARS-CoV-2 infection (termed Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC)) have driven research into the mechanisms and management of post-viral illness. Unlike historical outbreaks, researchers can now study post-viral syndromes as they develop.

What Are Post-Viral Syndromes?

Post-viral syndromes occur when symptoms persist long after the acute phase of a viral infection. These symptoms, including debilitating fatigue, cognitive dysfunction (“brain fog”), muscle or joint pain, and dizziness, may result from viral persistence in tissues or immune system dysfunction.

Examples of Viruses Associated with Post-Viral Syndromes

Epstein-Barr Virus (EBV)

EBV is a herpesvirus that infects over 90% of people worldwide. After acute EBV infection, it can remain in B cells, remaining dormant until stress or immune suppression triggers reactivation. EBV is strongly linked to ME/CFS, with studies suggesting it could trigger the condition in a subset of patients. It’s also associated with multiple sclerosis (MS) and some cancers, like lymphoma.

SARS-CoV-2 (COVID-19)

Long COVID, affecting 10–30% of people who had COVID-19, has increased attention on post-viral syndromes. Symptoms like persistent tiredness, shortness of breath, chest pain, and cognitive impairment can persist for months or years. The underlying cause remains unknown, though three mechanisms are under investigation:

1. Tiny blood clots within the lung damaging oxygen flow.
2. Persistent virus that harbours in the brain, muscle, gut or lungs.
3. Immune system dysfunction that can cause white blood cells to remain in an activated state as long as 8 months after initial infection.

Long COVID affects people of all ages, even those with mild initial infections, with millions of cases documented worldwide.

Human Herpesviruses (CMV, HHV-6)

Cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) are two more herpesviruses that can persist in the body after recovery. Like EBV, they remain dormant and may reactivate under immune stress. Symptoms can range from mild, flu-like symptoms (fever, aches and fatigue) to more severe issues such as vision problems and gastrointestinal issues in immunocompromised people.

Enteroviruses

These viruses, which include coxsackievirus, are linked to ME/CFS and other post-viral syndromes including Type 1 Diabetes. The virus may persist in tissues like the gut or nervous system, causing ongoing inflammation and symptoms. Certain mutations can cause enteroviruses to become less destructive to cells which allows them to remain in these tissues.

Mechanisms

The exact causes of post-viral syndromes remain unknown, but several mechanisms are candidates and undergoing investigation:

Viral Persistence

Some viruses and fragments do not fully clear from the body. For example, SARS-CoV-2 RNA has been found in tissues such as the gut, the brain, and lymph nodes months after infection. These remnants may trigger chronic inflammation or immune activation, causing symptoms.

Immune Dysregulation

Prolonged immune responses caused by persistent infection can lead to autoimmunity or immune exhaustion. In Long COVID, elevated inflammatory cytokines are common.

Mitochondrial Dysfunction

Mitochondria may be impaired by viral infections, reducing energy production and causing fatigue. EBV causes mitochondrial dysfunction by producing proteins like EBNA-1 that localise to mitochondrial membrane, impairing ATP production and disrupting energy metabolism.

Neurological Effects

Viruses like SARS-CoV-2 and EBV can affect the brain, either directly (by infecting neural tissue like neurons or glial cells) or indirectly (through triggering cytokine responses causing inflammation). This may explain cognitive issues, mood changes, and autonomic dysfunction.

Microbiome Disruption

The gut microbiome can be altered by viral infections. Dysbiosis (imbalanced gut bacteria caused by pathogenic microbes being favoured over beneficial microbes) may contribute to systemic inflammation and worsen symptoms. Some viruses can directly affect gut cells, altering microbial environments.

These mechanisms often interact and vary between patients.

The Diagnostic Challenge

Diagnosing post-viral syndromes is difficult. No single diagnostic test exists, and symptoms overlap with other conditions like fibromyalgia, thyroid disorders, or depression.

Diagnosis relies on:

• Clinical History: A known recent viral infection followed by persistent symptoms can point to a post-viral syndrome.
• Exclusion: This relies on other causes being ruled out through blood tests, imaging, or specialist referrals.
• Specific Tests: For some of the viruses there are specific tests, like EBV or CMV for example. Measuring antibody titres or performing PCR tests can detect past or persistent infection. For Long COVID, there are agreed diagnostic criteria from the WHO or CDC which concentrates on symptoms lasting over three months.

ME/CFS diagnosis often uses criteria like the Fukuda consensus criteria (1994), which include:

• Severe unexplained fatigue (must be new, persist for 6 months, no other explanation)
• Has excluded other conditions (e.g., depression, substance abuse, anaemia or sleep apnoea)
• At least four of the eight minor symptoms (memory issues, lymph node problems, muscle pain, joint pain, headaches, unrefreshing sleep and post exertion fatigue)

The lack of biomarkers to test for makes diagnostics difficult and rely on skilled medical professionals and patients often face scepticism from healthcare providers.

Treatment

Without a cure for most post-viral syndromes, treatment focuses on symptom relief and improving quality of life.

Common strategies include:

• Fatigue Management: Pacing (balanced activity, sleep, and rest) is recommended, though graded exercise therapy remains controversial in ME/CFS due to risks of symptom exacerbation. Pacing involves reducing activity to a baseline, monitoring symptoms, and distributing activities evenly rather than alternating between overexertion and rest.
• Cognitive Support: Cognitive behavioural therapy (CBT) and/or mindfulness can help with neurological issues such as brain fog and mood changes, though they don’t address the root causes. It can help develop coping strategies, challenge unhelpful beliefs about their fatigue, and improve sleep and physical activity management. Studies have shown that CBT can lead to a clinically significant reduction in fatigue and an improvement in physical functioning for many patients, including those with ME/CFS.
• Pain Relief: Analgesics, anti-inflammatories, and/or physical therapy may ease muscle and joint pain.
• Antiviral Therapies: Drugs like valganciclovir for EBV/CMV or Paxlovid (a combination of Nirmatrelvir (a protease inhibitor) and Ritonavir) for SARS-CoV-2 are being studied and show promise but aren’t yet being used as standard.
• Immune Modulation: Low-dose naltrexone (LDN) and intravenous immunoglobulin (IVIG) have shown promise in select cases. LDN was well tolerated and increased the SF-36 quality of life scores in patients.
• Lifestyle Changes: Optimising nutrition, hydration, and sleep can support overall health.
• Emerging Therapies: Anti-inflammatory drugs or mitochondrial boosters, are in early trials, but personalised treatment will remain key to this syndrome due to symptom variability.

Research is focused on addressing knowledge gaps in understanding these conditions’ mechanisms, improving diagnostics, and developing effective treatments.

Research in Post-Viral Syndrome Mechanisms

• Immune Dysregulation and Inflammation: Research is identifying how immune responses, inflammation, and autoimmunity contribute to post-viral syndrome. Studies are examining inflammatory cytokines (such as those triggered by NF-κB) crossing the blood-brain barrier, leading to neurotoxicity and inflammation that may cause fatigue and cognitive dysfunction.
• Viral Persistence: Research is investigating whether viral remnants or reactivation of latent viruses drive long-term symptoms. This includes identifying viral reservoirs in tissues and their impact on immune function, as well as strategies for viral clearance.
• Mitochondrial and Metabolic Dysfunction: Studies are investigating how viral infections impair mitochondrial function, leading to energy deficits and fatigue. For instance, SARS-CoV-2 disrupts cellular mitochondria, leading to widespread chronic inflammation and multi-organ dysfunction. Research is targeting mitochondrial metabolic pathways to understand their role in symptom persistence.
• Neuroinflammation and Autonomic Dysfunction: Research is mapping brain and nervous system abnormalities post-infection, such as dysregulation of the glymphatic system (the waste removal system for cerebrospinal fluid) or nervous system issues, which may explain symptoms like brain fog and dizziness upon standing.

The Path Ahead

Post-viral syndromes affect millions, yet effective treatments remain elusive. The mechanisms (viral persistence, immune dysregulation, mitochondrial dysfunction) are becoming clearer, but translating this knowledge into therapies takes time. Long COVID has accelerated research in ways unimaginable a decade ago. Whether this momentum delivers genuine breakthroughs remains to be seen, but for the first time in years, there’s reason for cautious optimism.

Blog by Paul Griffin

Supported by Reckon Better